{
  "abstract": "Introduction: Fecal calprotectin (FC) is established as a diagnostic marker to differentiate between inflammatory bowel diseases and non-inflammatory conditions. Furthermore, it may be effective in monitoring response to treatment, and to predict relapse during maintenance therapy. Design: This was a prospective longitudinal study carried out in Italy, France and Spain. The primary objective was to correlate the LIAISON® Calprotectin assay measurements to quiescent ulcerative colitis (UC) or relapse as assessed by clinical data. Patients were assessed every 3 months for 12 months, and at 18 months. Results: The last FC measured prior to relapse was the variable that predicted relapse in a statistically significant manner. With a 62.3 μg/g cut-off the area under the curve was 0.619, and the sensitivity was 62.9% (95% Confidence Interval [CI] 44.9%-78.5%) and specificity 63.0% (95% CI 53.1%-72.1%). Using machine learning methods, the last FC measurement was shown to have the largest impact in predicting relapse. An algorithm was developed that included other variables available following a clinician's visit, which resulted in an area under the curve of 0.754 for predicting relapse. Conclusion: In the present study FC measured by the LIAISON® Calprotectin assay on the visit before relapse is predictive of relapse in patients with quiescent UC. In a proof of concept, the accuracy of prediction can further be improved including other variables in an algorithm developed by machine learning. Trial registration: The trial is registered at clinicaltrials.gov with reference number NCT05168917.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "name": "Gionata Fiorino"
    },
    {
      "name": "Silvio Danese"
    },
    {
      "name": "Laurent Peyrin‐biroulet"
    },
    {
      "name": "Miquel Sans"
    },
    {
      "name": "Fabrizio Bonelli"
    },
    {
      "name": "Mariella Calleri"
    },
    {
      "name": "Claudia Zierold"
    },
    {
      "name": "Roberta Pollastro"
    },
    {
      "name": "Fabio Moretti"
    },
    {
      "name": "Alberto Malesci"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8kk82pb3zks8d.bib",
  "cited_by": 10,
  "doi": "10.1002/ueg2.12268",
  "fulltext_url": null,
  "id": "8kk82pb3zks8d",
  "issns": [
    "2050-6406",
    "2050-6414"
  ],
  "landing_url": "https://hal.univ-lorraine.fr/hal-04168200v1",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "1311|Inflammatory Bowel Disease"
    ]
  ],
  "openalex": "W4283805183",
  "pdf_url": "https://hal.univ-lorraine.fr/hal-04168200/document",
  "pmcid": null,
  "pmid": "35789124",
  "published": "2026-09-17",
  "publisher": "SAGE Publications",
  "ris": "https://research.draconitic.com/paper/8kk82pb3zks8d.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:35Z",
      "native_id": "hal-04168200",
      "source": "hal",
      "url": "https://hal.univ-lorraine.fr/hal-04168200v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:1311|Inflammatory Bowel Disease",
      "subfield": "genetics-genomics"
    }
  ],
  "title": "LIAISON ® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study",
  "title_text": "LIAISON ® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:35Z",
  "url": "https://research.draconitic.com/paper/8kk82pb3zks8d",
  "venue": "United European Gastroenterology Journal",
  "versions": []
}